非心脏动脉手术中氨甲环酸的疗效与安全性:系统综述与Meta分析
本系统综述与Meta分析评估非心脏动脉手术(NCAP)中使用氨甲环酸(TXA)的疗效与安全性,共纳入5项研究(n=4304)。Meta分析显示TXA不增加血栓栓塞并发症(RR 1.10;95%CI 0.71-1.70)或再手术率(RR 0.55;95%CI 0.19-1.63),但减少出血并发症的证据尚不充分。
要点
- Meta分析显示TXA不增加血栓栓塞并发症(RR 1.10;95%CI 0.71-1.70)或再手术率(RR 0.55;95%CI 0.19-1.63)。
- 颈动脉内膜切除术患者中TXA显著减少术后血肿(7.9% vs 1.3%;P=0.01),未增加血栓栓塞并发症或卒中。
- 目前证据尚不足以证明TXA减少NCAP中的出血并发症。
核心结论
- TXA不增加NCAP中血栓栓塞并发症的风险,但目前证据尚不足以证明TXA减少出血并发症。
研究设计与样本
- 系统综述与Meta分析,遵循PRISMA指南,检索PubMed、Embase和Cochrane数据库(2023年10月和2024年10月),纳入开放和血管内NCAP中研究TXA的研究,共5项研究(n=4304),Meta分析使用Cochrane Review Manager进行。
主要发现
- 一项非心脏手术中TXA的随机对照试验(n=9535)包含血管队列(14.8%;TXA组n=699,安慰剂组n=700),总体队列接受TXA者复合出血结局较低(9.5% vs 11.7%;P<0.001),但血管队列中无显著差异(风险比0.85;95%CI 0.64-1.13)。
- 另一项试验发现100例开放腹主动脉瘤手术患者的失血量或输血率无差异;两项试验均报告心血管或血栓栓塞并发症或30天死亡率未增加。
- 一项前瞻性研究显示创伤性血管损伤患者的血栓相关技术失败率相似(TXA组6.3% vs 3.8%,P=0.14),出血或血肿无显著差异(TXA组11.4% vs 4.3%,P=0.13)。
- 在297例颈动脉内膜切除术(CEA)患者中,TXA显著减少术后血肿(7.9% vs 1.3%;P=0.01),未增加血栓栓塞并发症或卒中;CEA术中止血方案中使用TXA(TXA组n=8)报告了相似结果。
- Meta分析显示血栓栓塞并发症(风险比1.10;95%CI 0.71-1.70)或再手术率(风险比0.55;95%CI 0.19-1.63)无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Noncardiac arterial procedures (NCAPs) are associated with a high risk of bleeding. Tranexamic acid (TXA) is used among surgical disciplines to reduce blood loss; however, its effectiveness and safety in NCAP remain unclear. This review evaluates the efficacy and safety of TXA during NCAP. METHODS: Systematic review and meta-analysis was performed in accordance with Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. Literature searches in PubMed, Embase, and Cochrane databases (October 2023 and October 2024) identified studies investigating TXA in open and endovascular NCAP. Meta-analyses were conducted using Cochrane's Review Manager. RESULTS: Five studies (n = 4304) were identified. One randomized controlled trial of TXA in noncardiac surgery (n = 9535), including a vascular cohort (14.8%; n = 699 TXA, n = 700 placebo), showed lower composite bleeding outcomes in the overall cohort receiving TXA (9.5% vs 11.7%; P < 0.001), but not in the vascular cohort (hazard ratio 0.85; 95% confidence interval [CI] 0.64-1.13). Another trial found no difference in blood loss or transfusion rates in 100 patients undergoing open abdominal aortic aneurysm surgery. Both trials reported no increased cardiovascular or thromboembolic complications (TECs) or 30-day mortality. A prospective study showed similar thrombosis-related technical failure rates in traumatic vascular injury patients (TXA 6.3% vs 3.8%, P = 0.14) and no significant differences in bleeding or hematoma (TXA 11.4% vs 4.3%, P = 0.13). In 297 carotid endarterectomy (CEA) patients, TXA significantly reduced postoperative hematoma (7.9% vs 1.3%; P = 0.01) without increasing TEC or stroke. TXA during an intraoperative hemostasis protocol during CEA (TXA n = 8) reported similar results. Meta-analysis showed no significant differences in TEC (risk ratio [RR] 1.10; 95% CI 0.71-1.70) or reoperation rates (RR 0.55; 95% CI 0.19-1.63). CONCLUSION: TXA does not increase the risk of TEC in NCAP. However, there is currently insufficient evidence that TXA reduces bleeding complications.
引用
- Steunenberg TAH, Bakker NC, Wiersema AM, et al. Efficacy and Safety of Tranexamic Acid in Noncardiac Arterial Procedures: A Systematic Review and Meta-Analysis. Ann Vasc Surg. 2025. PMID: 40157449. doi:10.1016/j.avsg.2025.03.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。